REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
JOURNAL OF CLINICAL ONCOLOGY. Bd. 36. H. 15. 2018
Erscheinungsjahr: 2018
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Zhu, Andrew X. (Autor)
Kang, Yoon-Koo (Autor)
Yen, Chia-Jui (Autor)
Finn, Richard S. (Autor)
Galle, Peter R. (Autor)
Llovet, Josep M. (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
